Amy E. Dezern

Amy E. Dezern

Oncology | Hematology

401 North Broadway Street, Weinberg BLDG
Weinberg BLDG
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 245 publications

Donor Related Logistical Challenges in Hematopoietic Transplant: A Comparative Analysis of Related and Unrelated Donors.

Donor Related Logistical Challenges in Hematopoietic Transplant: A Comparative Analysis of Related and Unrelated Donors.

Journal: Transplantation and cellular therapy

Published: July 25, 2026

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Journal: American journal of hematology

Published: June 25, 2026

SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.

SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 02, 2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Journal: Blood cancer journal

Published: March 13, 2026

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal: Leukemia & lymphoma

Published: February 15, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica

Published: February 15, 2026

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.

Journal: Haematologica

Published: February 11, 2026

VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 1: Epidemiology, Pathophysiology, and Clinical Presentations.

VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 1: Epidemiology, Pathophysiology, and Clinical Presentations.

Journal: Journal of the American Academy of Dermatology

Published: February 09, 2026

VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 2: Work-up, Diagnosis, Treatment, and Prognosis.

VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 2: Work-up, Diagnosis, Treatment, and Prognosis.

Journal: Journal of the American Academy of Dermatology

Published: February 09, 2026

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Journal: Blood

Published: January 08, 2026

PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

Journal: Blood advances

Published: January 05, 2026

PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

Journal: Blood advances

Published: January 05, 2026

Showing 1-12 of 245

Last Updated: 09/26/2026